[go: up one dir, main page]

CA2132688A1 - Anti-septic, spermicidal composition and means for its application - Google Patents

Anti-septic, spermicidal composition and means for its application

Info

Publication number
CA2132688A1
CA2132688A1 CA002132688A CA2132688A CA2132688A1 CA 2132688 A1 CA2132688 A1 CA 2132688A1 CA 002132688 A CA002132688 A CA 002132688A CA 2132688 A CA2132688 A CA 2132688A CA 2132688 A1 CA2132688 A1 CA 2132688A1
Authority
CA
Canada
Prior art keywords
amount
formulation
composition
applicator
vaginal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002132688A
Other languages
French (fr)
Inventor
George Martyn Livingston
David B. Thornburgh
Jeffrey Longmore
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GEDA International Marketing Co Ltd
Original Assignee
GEDA International Marketing Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GEDA International Marketing Co Ltd filed Critical GEDA International Marketing Co Ltd
Priority to CA002132688A priority Critical patent/CA2132688A1/en
Publication of CA2132688A1 publication Critical patent/CA2132688A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N31/00Biocides, pest repellants or attractants, or plant growth regulators containing organic oxygen or sulfur compounds
    • A01N31/08Oxygen or sulfur directly attached to an aromatic ring system
    • A01N31/14Ethers
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N33/00Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
    • A01N33/02Amines; Quaternary ammonium compounds
    • A01N33/12Quaternary ammonium compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F6/00Contraceptive devices; Pessaries; Applicators therefor
    • A61F6/06Contraceptive devices; Pessaries; Applicators therefor for use by females
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • A61K31/085Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/14Quaternary ammonium compounds, e.g. edrophonium, choline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention provides a spermicidally and virucidally effective, vaginally applicable formulation, having the following approximate composition of essential ingredients:
at least one benzalkonium chloride, in an amount from 0.05 to 0.2%;
at least one spermicide selected from the group consisting of nonoxynols in an amount of from 0.05-12%, octoxynol-9 in an amount of from 0.05-4%, and triclosan in an amount from 0.05-2%;
a biologically acceptable emollient, in an amount from 1-5%;
hydroxypropylmethyl cellulose, in an amount from 0.1-3%;
sodium carbomer, in an amount from 0.1-1%;
de-ionized water, making up the balance. The composition has the attributes of (a) a semi-solid, essen-tially clear gel consistency and appearance, and (b) the ability to maintain a presence in the human vagina in the presence of mucous secretions therein, in virucidally effective amounts, for at least 24 hours after application thereto.

Description

- 1 - 21~2688 This invention relates to antiseptic spermicidal compositions, and more particularly to antiseptic spermicidal compositions for vaginal application, to protect against transmission of sexually transmitted viruses and other infections, and to protect against conception. It also relates to means for effective applica-tion of such compositions.

Transmission of infection from body to body as a result of sexual intercourse is one of the principal ways in which viruses such as herpes 1 and 2, HIV, cytomegalo-virus, hepatitis B and the like, and venereal bacterial diseases such as gonorrhea, chancroid, streptococcus, staphylococcus, gardnerella, mycobacteria, etc are spread.
Particularly at risk from such infection transmissions are highly sexually active females, e.g. those engaged in the sex trade, who at the same time run high risks of unwanted pregnancy. To date, the most commonly recommended form of protection against such risks has been the use of latex condoms, optionally in conjunction with a spermicidal lubricant. This however depends upon co-operation of the male partner, and does not provide the female participant with full control over the risks to her own body.

Of particular concern in this regard are condi-tions in emerging, third-world countries, where the avail-ability condoms and spermicidal or germicidal compositions for use therewith is very restricted. The spread of infec-tious disease, and population control, are items of especial concern. The problems are complicated by the relative lack of expert medical facilities in many such countries, and the educational level of the population at risk.

Any antiviral and contraceptive system having a chance of being accepted, widely used and effective in such places must therefore be simple to use, by the woman - 2 - 21~268~

herself, without expert medical assistance. It should be capable of being applied well in advance of the time when the sexual activity is to take place and to remain effec-tive for a substantial period of time thereafter. Moreover it should be physically and aesthetically pleasant, so that it does not detract unnecessarily from the sexual activity.

It is an object of the present invention to provide a novel spermicidally effective and virucidally effective composition for female use.

It is a further object of the invention to provide a kit and method for use of such a composition.

SUMMARY OF THE INVENTION

The present invention provides a clear gel formulation for vaginal application, which is contracep-tively effective as a spermicide, and antivirally effective to prevent HIV transmission. A formulation has been found which can be applied to the vaginal walls, and will remain thereon in quantities or concentrations to confer effective protection against HIV reception by the female for at least 24 hours following application, without exhibiting harmful effects to these very sensitive mucous-bearing skin sur-faces. The formulation contains a very small amount of a strong disinfectant namely one or more benzalkonium chlor-ides, and a spermicidal substance such as an octoxynol-9, a nonoxynol, and/or triclosan, along with sodium carbomer and other inert ingredients carefully chosen as to both nature and quantity so as to provide a clear semi-solid gel capable of remaining on the vaginal walls for at least 24 hours after application, in a virucidally effective form.

Thus, according to the present invention, from one aspect, there is provided a spermicidally and virucidally effective, vaginally applicable formulation, ~ 3 - 2132688 having the following approximate composition of essential ingredients:
at least one benzalkonium chloride, in an amount from 0.05 to 0.2~;
at least one spermicide selected from the group consisting of nonoxynols in an amount of from 0.05-12~, octoxynol-9 in an amount of from 0.05-4~, and 5-chloro-2-(2,4-dichlorophenoxy)phenol in an amount from 0.05-2~;
a biologically acceptable emollient, providing appropriate consistencyi hydroxypropylmethyl cellulose, in an amount from 0.1-3~;
sodium carbomer, in an amount from 0.1-1~;
de-ionized water, making up the balance, the formulation further possessing the attributes of (a) a semi-solid, essentially clear gel consistency and appear-ance, and (b) the ability to maintain a presence in the human vagina along with mucous secretions therein, in virucidally effective amounts, for at least 24 hours after application thereto.

Another aspect of the present invention provides a kit for vaginal self-use by a female patient in protec-tion against contracting viral infection and against conception as a result of normal heterosexual intercourse, said kit comprising a vaginal applicator comprising a vaginally insertable tubular member having a length of about five inches, and having an aperturable distal end adapted to be positioned adjacent to the patient's cervix when the applicator is fully inserted into the patient's vagina, and at least one unit dose of the spermicidally and virucidally effective formulation described above, said unit dose being from about 5-10 mls thereof.

In the accompanying drawings:

FIGURE 1 is a side view of an applicator for use in the kit of the present invention;

FIGURE 2 is a cross sectional view of the appli-cator of Fig. 1, along the line 1-1 of Fig. 1.

The benzalkonium chlorides used in the present invention are known compounds, many of which have previous-ly been sold and used for disinfecting purposes in non-skin contacting applications. Thus, they are sold for purposes of making up a disinfectant wash solutions for floors, walls, operating surfaces and the like, but always with strong warnings to avoid skin contact with them if at all possible. They are powerful poisons and skin irritants, as well as powerful disinfectants. The present invention takes advantage of the fact, hitherto unreported, that they will destroy harmful viruses such as herpes simplex types 1 and 2 and HIV when they are present in formulations in such low concentrations that they acceptable on and non-harmful to the human vaginal walls. These viruses in fact are not difficult to kill when encountered in isolation in external body fluids or secretions. It is after they have infected the m~mm~l ian body and become to replicate in the body cells that they become almost impossible to treat effec-tively. If the viruses can be caught and treated on transmission from body to body, they are w lnerable to common disinfectants such as those used in the compositions of the present invention.

To safeguard against risks of skin irritation, the benzalkonium chloride is preferably used in the compo-sition of the present invention in amounts from 0.05-0.12~
by weight. Specific examples of benzalkonium chlorides for use in the present invention include alkyl dimethyl benzyl ammonium chloride and alkyl dimethylethylbenzyl ammonium chloride, in which the alkyl portions are C12-C18 in length, and mixtures thereof, and myristylbenzalkonium chloride.

213~68~
Such a suitable mixture is available commercially under the trade name MAQUAT MQ2525M - 50~, from Mason Chemical Company, Chicago, Illinois, and under the trade name BTC
2125M from Stepan Company, North Field, Illinois.

Compositions according to the present invention also include a small but effective amount of a spermicide.
The spermicide is selected from nonoxynols, octoxynol-9 and triclosan [which is, chemically, 5-chloro-2-(2,4-dichloro-phenoxy)phenol)], and are used in the amounts set out above. The octoxynol series are polyethylene glycol p-isooctylphenyl ethers such as octoxynol-9 (Triton X - 100).
The nonoxynol series are polyoxyethylene nonylphenyl ethers, of various numbers of ethylene oxide units, e.g. -nonoxynol 9 and nonoxynol 10. They also confer surfactant properties on the compositions of the invention, making them easier to spread over the surface of the vaginal walls.

Whilst the various additional ingredients added to the composition of the present invention are in a sense carriers, in that they are not virucidally or spermicidally active, they nevertheless play important roles in determin-ing the nature and thereby rendering the compositions acceptable for use. The combination of the emollient (which is preferably glycerine), sodium carbomer and hydroxypropylmethyl cellulose in the specified relative amounts in the formulation of the invention ensures a semi-solid clear gel composition, which is a very important factor in the acceptability of the composition for its intended use. Opaque, coloured compositions will not gain consumer acceptance for vaginal use as a protectant against sexually transmitted infections.

Even more important is the fact that the composi-tion of the invention has its inert ingredients selected and present in amounts which ensure a gel which is long lasting in its effectiveness after application. The combi-nation of the hydroxypropylmethyl cellulose and the sodium carbomer in the specified proportions ensures a composition of sufficient adherence to the patients' vaginal walls that it remains effective against HIV transmission for at least 24 hours. Accordingly the patient needs only a single daily self-application of the composition of the present inven-tion, to obtain the required protection. She has total and sole control over this protection for herself, without reliance on partners or medical practitioners.

The composition of the present invention contains one or more emollients such as glycerine, lanolin, aloe vera, paraffin oils, glycerol monostearate, myrj compounds, Tween, PEG compounds, sodium lauryl sulphate, etc., and mixtures of two or more of them, to improve the lubricity and general oiliness of the composition. Glycerine is the preferred emollient. It can also if desired contain various perfumes. Any ingredients which are used must be skin compatible, inert towards the active ingredients, and of a nature and used in an amount which does not destabilize or upset the general consistency of the formulation.

Sodium carbomer used as a key ingredient in the composition of the present invention to provide the necess-ary consistency for long lasting (minimum 24 hour) action, is a known substance. It is the sodium salt of carbopol, which in turn is a polymer of acrylic acid having free carboxyl groups, which is dispersed in water to form a slight gel. Then a suitable water soluble base such as sodium hydroxide is added, forming a salt and affecting the conformation of the polymer in solution and causing high gelling effect. Various grades of carbopol are available, having different acid values and molecular weights.
The formulations according to the present inven-tion can be prepared using standard cosmetic or pharma-~13~688 ceutical gel formulating procedures and equipment. There is no particular, critical order of addition of components, mixing temperatures or the like, provided that a homogene-ous, reasonably stable end product is achieved.

The composition of the present invention is useful as a spermicide and antiseptic, alone or in combina-tion with a condom or a diaphragm. It is a topical intra-vaginal gel which is water soluble but has the property of remaining in the vagina for extended periods of time. It helps protect against the transmission of various sexually transmitted diseases such as viral (HIV or AIDS, herpes, hepatitis B cytomegalovirus), chlamydia, trichomonas, various bacteria including gonorrhea and G. Vaginalis and test strain of Treponema phagedenis, a surrogate for syphilis. It is not harmful to epithelium but will destroy lymphocytes and macrophages which carry the AIDS virus or HIV in persons infected with AIDS.

The composition of the present invention is specially formulated for vaginal self-application by females. The female adult vagina is normally about five inches in length, and it is important that, for maximum effectiveness, the composition be disposed all the way along the vaginal wall, and particularly at the inner end thereof, adjacent to the cervix. Accordingly, a preferred embodiment of the present invention provides the composi-tion as described above in combination with an applicator which the patient can use to ensure proper application of composition to the most beneficial location. The applicator is a vaginally insertable elongated object about five inches in length, adapted to receive and dispense the formulation. In one preferred embodiment, the applicator is a once usable tube containing a single dosage of formu-lation, and has an aperture, preferably equipped with a rupturable removable cap, provided at the distal end there-of, i.e. the end to be disposed adjacent to the patient's - 8 - ~132~88 cervix on full and proper insertion into the vagina. The internal volume of the tubular applicator is about 8.5 ml, which allows discharge of the appropriate dosage of compo-sition to be administered. Normally about 5 ml of formula-tion should be discharged. The remainder remains in, and is discarded with, the applicator. Another form of appli-cator is equipped with a plunger which can be operated to empty the internal cavity of the tube through the distal end opening. The tube is filled with the appropriate dosage of composition, inserted fully into the vagina, and the plunger is operated to empty it as it is withdrawn there-from. The length of the applicator ensures that an effec-tive amount of the composition is disposed at the cervical end of the vagina, for maximum protection.
The specific, most preferred formulation for use in the present invention has the following composition (percentages by weight):

Carbopol 934P 0.40 sodium hydroxide 0.10 hydroxypropylmethyl cellulose K4M 1.50 Glycerin 2.27 Triton X-100 (octoxynol-9) 0.20 Benzalkonium chloride(MQ 2525-50~) 0.20 Water balance to 100~

The accompanying drawings diagrammatically illustrate an applicator for use with compositions of the present invention. The apparatus is an elongated tube of total length about 5 inches, having an oval shape as seen in cross section (Fig. 2) On the distal end 12 is a remov-able or rupturable cap 14 covering an aperture 16. The internal cavity is filled with clear gel composition according to the invention, a quantity of about 8.0 ml. On the proximal end 18 is an integral squeezable reservoir 20, which is used to discharge the contents into the patient~s vagina after full insertion of the device into the patient~s vagina. The device is factory filled with a single dosage, sealed at the factory, and used once and discarded.

The invention is further described and illus-trated in the following specific, non limiting examples.

o A clear gel formulation according to specific, most preferred embodiment of the invention as detailed above was made. The preparation was made by simple mixing of ingredients in a container, at room temperature. Three normal female volunteers agreed to instill 5 ml of the formulation intravaginally and retrieve samples of vaginal secretions from the deep lateral wall of the vagina at varying intervals up to eight hours after instillation. One subject submitted samples eight hours after sexual inter-) course (confirmed microscopically). The various samples were assessed for anti-HIV inhibitory activity.

All specimens, even when diluted 10:1, showed excellent activity in subsequent standard in vitro tests against HIV-1. The similar use of a composition of the same active ingredients but omitting the sodium carbomer, and hence having a lotion-like consistency rather than the semisolid gel consistency of the compositions of the invention, yielded a secretion sample which had adequate activity for a short period of time, but at eight hours did not show such activity. Also, the volunteer who used it complained that it rapidly drained from the vagina.

This experiment was conducted to determine the length of time that the composition of the invention, as - - 10 - ~13~8 used in Example 1 above, instilled vaginally, will render vaginal secretions sterile to HIV.

Two HIV seropositive females with previously detectable HIV from vaginal fluids by culture and RNA PCR
were selected and studied. Both women had histories of frequent sexual activity and intravenous drug use, T4 counts >200/cu,mm and were known to be HIV infected for greater than 5 years. 1-2 ml of vaginal secretions were 0 aspirated with a pipette from the posterior fornix and vaginal secretions were obtained for HIV studies. HIV RNA
PCR and HIV cultures were performed in the standard manner (MT-2 syncytium-inhibition assay). 5.5 ml of the composi-tion of the invention was instilled into the posterior fornix and the women were asked to maintain normal daily activities and to refrain from sexual intercourse. The women were not menstruating. Prior to the installation of the composition and after 8 and 24 hours from installation, samples were obtained for HIV studies.
o In both patients with previously detectable HIV
by cultures and RNA from cervical secretions, no virus was detected for 24 hours after the application of the composi-tion. It can thus be concluded that the composition of the invention, when administered as described herein, is capable of maintaining vaginal secretions sterile to HIV
for at least 24 hours.

Claims (5)

1. A spermicidally and virucidally effective, vaginally applicable formulation, having the following approximate composition of essential ingredients:
at least one benzalkonium chloride, in an amount from 0.05 to 0.2%;
at least one spermicide selected from the group consisting of nonoxynols in an amount of from 0.05-12%, octoxynol-9 in an amount of from 0.05-4%, and 5-chloro-2-(2,4-dichlorophenoxy)phenol in an amount from 0.05-2%;
a biologically acceptable emollient, to provide appropriate consistency;
hydroxypropylmethyl cellulose, in an amount from 0.1-3%;
sodium carbomer, in an amount from 0.1-1%;
de-ionized water, making up the balance, the formulation further possessing the attributes of (a) a semi-solid, essentially clear gel consistency and appearance, and (b) the ability to maintain a presence in the human vagina along with mucous secretions therein, in virucidally effective amounts, for at least 24 hours after application thereto.
2. The formulation of claim 1 wherein the emollient is glycerine.
3. The formulation of claim 2 wherein the glycerine is present in an amount from 1-10%.
4. A kit for vaginal self-use by a female patient in protection against contracting viral infection and against conception as a result of normal heterosexual intercourse, said kit comprising a vaginal applicator comprising a vaginally insertable tubular member having a length of about five inches, and having an aperturable distal end adapted to be positioned adjacent to the patient's cervix when the applicator is fully inserted into the patient's vagina, and at least one unit dose of the spermicidally and virucidally effective formulation of claim 1, said unit dose being from about 5-10 mls thereof.
5. The kit of claim 4 wherein the applicator has a squeezable reservoir containing said formulation, in communication with said tubular member.
CA002132688A 1994-09-22 1994-09-22 Anti-septic, spermicidal composition and means for its application Abandoned CA2132688A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002132688A CA2132688A1 (en) 1994-09-22 1994-09-22 Anti-septic, spermicidal composition and means for its application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002132688A CA2132688A1 (en) 1994-09-22 1994-09-22 Anti-septic, spermicidal composition and means for its application

Publications (1)

Publication Number Publication Date
CA2132688A1 true CA2132688A1 (en) 1996-03-23

Family

ID=4154381

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002132688A Abandoned CA2132688A1 (en) 1994-09-22 1994-09-22 Anti-septic, spermicidal composition and means for its application

Country Status (1)

Country Link
CA (1) CA2132688A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010744A1 (en) * 1996-09-12 1998-03-19 Simon Everard Barton Composition comprising an antiviral or antibacterial agent for preventing transmission of diseases
EP0862441A4 (en) * 1995-10-24 1999-11-17 Marshall University Research C Vaginal pharmaceutical compositions containing a peroxide source
WO2000072839A1 (en) * 1999-05-26 2000-12-07 Optima Holding Co. Antiseptic spermicidal composition and means for its application
US7338927B2 (en) 2002-08-20 2008-03-04 Alda Pharmaceuticals Corp. Wide spectrum disinfectant comprising an alcohol and disinfectant mixture
US7566740B2 (en) * 1998-10-06 2009-07-28 Bml Pharmaceuticals, Inc. Method of treating mucositis

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0862441A4 (en) * 1995-10-24 1999-11-17 Marshall University Research C Vaginal pharmaceutical compositions containing a peroxide source
WO1998010744A1 (en) * 1996-09-12 1998-03-19 Simon Everard Barton Composition comprising an antiviral or antibacterial agent for preventing transmission of diseases
US7566740B2 (en) * 1998-10-06 2009-07-28 Bml Pharmaceuticals, Inc. Method of treating mucositis
WO2000072839A1 (en) * 1999-05-26 2000-12-07 Optima Holding Co. Antiseptic spermicidal composition and means for its application
US7338927B2 (en) 2002-08-20 2008-03-04 Alda Pharmaceuticals Corp. Wide spectrum disinfectant comprising an alcohol and disinfectant mixture
US7560422B2 (en) 2002-08-20 2009-07-14 Alda Pharmaceuticals Corp. Alcohol-based wide spectrum disinfectant comprising nonoxynol-9

Similar Documents

Publication Publication Date Title
US5545401A (en) Antiviral, spermicidal vaginal gel and foam containing low molecular weight povidone-iodine
RU2274442C2 (en) Compositions and methods for entrapping and inactivation of pathogenic microorganisms and spermatozoids
EP0784466B1 (en) Use and composition of an anti-sexually transmitted diseases formulation
DK173527B1 (en) Pharmaceutical preparation for the prevention of sexually transmitted diseases
US6328991B1 (en) Composition and method for prevention of sexually transmitted diseases, including aids
AU2001243431A1 (en) Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa
Elias et al. Colposcopic evaluation of a vaginal gel formulation of iota-carrageenan
CA2640978C (en) Contraceptive composition
US5137718A (en) Infection fighting composition for topical application
US7718642B2 (en) AIDS prophylactic lubricating composition
US5778886A (en) Vaginal compositions combining a spermicidal agent and a peroxygen compound
US8518434B2 (en) Antiseptic spermicidal composition and means for its application
CA2132688A1 (en) Anti-septic, spermicidal composition and means for its application
US6949255B2 (en) Inhibitory chemical formulation with preservative system
CA1326446C (en) Substance or pharmaceutical or cosmetic composition inhibition or destroying at least one unicellular living creature and/or at least one virus, drug or product containing such a substance, process of manufacture of such substance, chemical compound included in such substance, and process of inhibition or destruction of at least one...
WO2000072839A1 (en) Antiseptic spermicidal composition and means for its application
AU783242B2 (en) Methods and devices for preventing transmission of sexually transmitted diseases
US20050241645A1 (en) Composition for preventing the transmission of human immunodeficiency syndrome virus
GB2318292A (en) Saliva-like protectants

Legal Events

Date Code Title Description
FZDE Discontinued